Pasar al contenido principal

-

IJCI-2014-19381

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differential effects of metformin glycinate and hydrochloride in glucose production, AMPK phosphorylation and insulin sensitivity in hepatocytes from non-diabetic and diabetic mice

  • Rada, Patricia
  • Mosquera, Alejandra
  • Muntané, Jordi
  • Ferrandiz, Francisco
  • Rodríguez-Mañas, Leocadio
  • Pablo, Flora de
  • González-Canudas, Jorge
  • Valverde, Ángela M.
The liver is a main target tissue of the biguanide metformin which activates AMP-activated protein kinase (AMPK). We previously reported that administration of metformin glycinate showed a greater decrease of glycated hemoglobin A1c than a placebo in patients with type 2 diabetes mellitus (T2DM). In this study, we compared the effects of metformin hydrochloride, the oral antidiabetic drug of first choice, with those of metformin glycinate in hepatocytes from non-diabetic and diabetic mice and humans. Both formulations were equally potent regard to the reduction of basal and glucagon-induced glucose production and mRNA levels of gluconeogenic enzymes (Pck1 and G6pc) in hepatocytes from C57/Bl6 mice and humans. On the contrary, phosphorylation of AMPK and its substrate acetyl CoA carboxylase (ACC) was faster in hepatocytes treated with metformin glycinate. Likewise, we found stronger reduction in hepatocytes from obese/diabetic db/db mice of glucagon-induced glucose output and more sustained AMPK phosphorylation after treatment with metformin glycinate. Importantly, insulin sensitization regarding phosphorylation of AKT (Ser473) was enhanced in hepatocytes from db/db mice or humans pretreated with metformin glycinate. In conclusion, our data indicate that metformin glycinate may be an alternative therapy against insulin resistance during obesity and/or T2DM., Financial support was received from Laboratorios Silanes S.A. de C.V. (Project reference 20159770) as a research agreement with the Instituto de Investigaciones Biomedicas Alberto Sols (CSIC). This work was also funded by grants SAF2015-65267-R (MINECO/FEDER), S2017/BMD-3684 MOIR2-CM (Comunidad de Madrid, Spain), CIBERdem (ISCIII, Spain), and H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission) to A.M.V. and IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SIRT1 controls acetaminophen hepatotoxicity by modulating inflammation and oxidative stress

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz, Laura
  • González-Rodríguez, Águeda
  • Sánchez-Ramos, Cristina
  • Muntané, Jordi
  • Alemany, Susana
  • James, Laura P.
  • Simpson, Kenneth J.
  • Monsalve, María
  • Valdecantos, M. P.
  • Valverde, Ángela M.
ARS Open., [Aims]: Sirtuin 1 (SIRT1) is a key player in liver physiology and a therapeutic target against hepatic inflammation. We evaluated the role of SIRT1 in the proinflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 on APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, proinflammatory cytokine messenger RNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin (IL)1β, an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Inovation]: Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant., [Rebound Track]: This work was rejected during standard peer review and rescued by Rebound Peer Review (Antioxid Redox Signal 16:293-296, 2012) with the following serving as open reviewers: Rafael de Cabo, Joaquim Ros, Kalervo Hiltunen, and Neil Kaplowitz. Antioxid. Redox Signal. 28, 1187-1208., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), and INFLAMES (ISCIII PIE14/00045, cofunded by ERDF, ‘‘Investing in your future’’) to A.M.V.; IJCI-2014-19381 (MINECO/FEDER) to P.R. and A.M.V.; SAF2014-52009-R (MINECO/FEDER) to S.A.; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A.G.-R.; and PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII) to A.G.-R. and J.M.; Grant 37/371 from Al Jouf University to M.A.M. We also acknowledge H2020 Marie Sklodowska-Curie ITNTREATMENT (Grant Agreement No. 721236) (European Commission)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protection against gamma-radiation injury by protein tyrosine phosphatase 1B

  • Mojena, Marina
  • Pimentel-Santillana, María
  • Povo-Retana, Adrián
  • Fernández-García, Victoria
  • González-Ramos, Silvia
  • Rada, Patricia
  • Tejedor, Alberto
  • Rico, Daniel
  • Martín-Sanz, Paloma
  • Valverde, Ángela M.
  • Boscá, Lisardo
Protein tyrosine phosphatase 1B (PTP1B) is widely expressed in mammalian tissues, in particular in immune cells, and plays a pleiotropic role in dephosphorylating many substrates. Moreover, PTP1B expression is enhanced in response to pro-inflammatory stimuli and to different cell stressors. Taking advantage of the use of mice deficient in PTP1B we have investigated the effect of γ-radiation in these animals and found enhanced lethality and decreased respiratory exchange ratio vs. the corresponding wild type animals. Using bone-marrow derived macrophages and mouse embryonic fibroblasts (MEFs) from wild-type and PTP1B-deficient mice, we observed a differential response to various cell stressors. PTP1B-deficient macrophages exhibited an enhanced response to γ-radiation, UV-light, LPS and S-nitroso-glutathione. Macrophages exposed to γ-radiation show DNA damage and fragmentation, increased ROS production, a lack in GSH elevation and enhanced acidic β-galactosidase activity. Interestingly, these differences were not observed in MEFs. Differential gene expression analysis of WT and KO macrophages revealed that the main pathways affected after irradiation were an up-regulation of protein secretion, TGF-β signaling and angiogenesis among other, and downregulation of Myc targets and Hedgehog signaling. These results demonstrate a key role for PTP1B in the protection against the cytotoxicity of irradiation in intact animal and in macrophages, which might be therapeutically relevant., This work was supported by grants SAF2017-82436R, SAF2016-75004R and SAF2015-65267 from MINIECO, S2017/BMD-3686 and BMD3684 from Comunidad de Madrid, Fundación Ramón Areces (2016/CIVP18A3864) and Cibercv, Ciberdem and Ciberehd (funded by the Instituto de Salud Carlos III and by Fondos FEDER). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission). P.R. was recipient a Juan de la Cierva postdoctoral contract from MINIECO (IJCI-2014-19381)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

  • González-Rodríguez, Águeda
  • Valdecantos, M. P.
  • Rada, Patricia
  • Addante, Annalisa
  • Barahona, Inés
  • Rey, Esther
  • Pardo, Virginia
  • Ruiz, Laura
  • Laiglesia, Laura M.
  • Moreno-Aliaga, María Jesús
  • García-Monzón, Carmelo
  • Sánchez, Aránzazu
  • Valverde, Ángela M.
[Objectives]: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries. Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity. We investigated the impact of PTP1B deficiency during NAFLD, particularly in non-alcoholic steatohepatitis (NASH). [Methods]: NASH features were evaluated in livers from wild-type (PTP1BWT) and PTP1B-deficient (PTP1BKO) mice fed methionine/choline-deficient diet (MCD) for 8 weeks. A recovery model was established by replacing MCD to chow diet (CHD) for 2–7 days. Non-parenchymal liver cells (NPCs) were analyzed by flow cytometry. Oval cells markers were measured in human and mouse livers with NASH, and in oval cells from PTP1BWT and PTP1BKO mice. [Results]: PTP1BWT mice fed MCD for 8 weeks exhibited NASH, NPCs infiltration, and elevated Fgf21, Il6 and Il1b mRNAs. These parameters decreased after switching to CHD. PTP1B deficiency accelerated MCD-induced NASH. Conversely, after switching to CHD, PTP1BKO mice rapidly reverted NASH compared to PTP1BWT mice in parallel to the normalization of serum triglycerides (TG) levels. Among NPCs, a drop in cytotoxic natural killer T (NKT) subpopulation was detected in PTP1BKO livers during recovery, and in these conditions M2 macrophage markers were up-regulated. Oval cells markers (EpCAM and cytokeratin 19) significantly increased during NASH only in PTP1B-deficient livers. HGF-mediated signaling and proliferative capacity were enhanced in PTP1BKO oval cells. In NASH patients, oval cells markers were also elevated. [Conclusions]: PTP1B elicits a dual role in NASH progression and reversion. Additionally, our results support a new role for PTP1B in oval cell proliferation during NAFLD., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; CP14/00181 and PI16/00823 (ISCIII/FEDER) and CIBERehd (ISCIII, Spain) to A.G-R; BFU2015-65937-R (MINECO/FEDER), 67-2015 (Department of Health, Navarra Government) and CIBERobn (ISCIII, Spain) to M.J.M; SAF2015-69145-R (MINECO/FEDER) to A.S. A.A. was recipient of a Marie Curie ESR contract from IT-LIVER (Marie Curie Action of the FP7-2012, grant agreement 316549). We also acknowledge the European Union, project H2020-MSCA-ITN TREATMENT Grant Agreement number: 721236., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases

  • García-Ruiz, Inmaculada
  • Blanes Ruiz, Nerea
  • Rada, Patricia
  • Pardo, Virginia
  • Ruiz, Laura
  • Blas-García, Ana
  • Valdecantos, M. P.
  • Grau Sanz, Montserrat
  • Solís-Herruzo, José A.
  • Valverde, Ángela M.
Inflammation is typically associated with the development of fibrosis, cirrhosis and hepatocellular carcinoma. The key role of protein tyrosine phosphatase 1B (PTP1B) in inflammatory responses has focused this study in understanding its implication in liver fibrosis. Here we show that hepatic PTP1B mRNA expression increased after bile duct ligation (BDL), while BDL-induced liver fibrosis was markedly reduced in mice lacking Ptpn1 (PTP1B−/−) as assessed by decreased collagen deposition and α-smooth muscle actin (α-SMA) expression. PTP1B−/− mice also showed a significant increase in mRNA levels of key markers of monocytes recruitment (Cd68, Adgre1 and Ccl2) compared to their wild-type (PTP1B+/+) littermates at early stages of injury after BDL. Interestingly, the lack of PTP1B strongly increased the NADPH oxidase (NOX) subunits Nox1/Nox4 ratio and downregulated Cybb expression after BDL, revealing a pro-survival pattern of NADPH oxidase induction in response to liver injury. Chimeric mice generated by transplantation of PTP1B−/− bone marrow (BM) into irradiated PTP1B+/+ mice revealed similar hepatic expression profile of NOX subunits than PTP1B−/− mice while these animals did not show differences in infiltration of myeloid cells at 7 days post-BDL, suggesting that PTP1B deletion in other liver cells is necessary for boosting the early inflammatory response to the BDL. PTP1B−/− BM transplantation into PTP1B+/+ mice also led to a blockade of TGF-β and α-SMA induction after BDL. In vitro experiments demonstrated that deficiency of PTP1B in hepatocytes protects against bile acid-induced apoptosis and abrogates hepatic stellate cells (HSC) activation, an effect ameliorated by NOX1 inhibition. In conclusion, our results have revealed that the lack of PTP1B switches NOX expression pattern in response to liver injury after BDL and reduces HSC activation and liver fibrosis., This work was funded by grants SAF2015-65267-R and RTI2018-094052-B-100 (MICINN/FEDER, Spain), S2017/BMD-3684 MOIR2-CM (Comunidad de Madrid, Spain) and CIBERdem (ISCIII, Spain) to A.M.V; IJCI-2014-19381 (MINECO/FEDER, Spain) to P.R and A.M.V. We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement 721236, European Commission)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Modulation of SIRT1 by IL1b/NFkB signaling during acetaminophen-induced hepatotoxicity

  • Rada, Patricia
  • Pardo, Virginia
  • Mobasher, Maysa A.
  • García Martínez, Irma
  • Ruiz-Cañas, Laura
  • Sánchez-Ramos, Cristina
  • Alemany, Susana
  • Monsalve, María
  • Valverde, Ángela M.
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018., [Introduction]: The liver is the main organ in charge of drug catabolism and also the major site susceptible to drug injury. Sirtuin 1 (SIRT1), a NAD+-dependent histone deacetylase, is a key player in liver physiology and a therapeutic target against hepatic inflammation. In this study, we evaluated the role of SIRT1 in the pro-inflammatory context and oxidative stress during acetaminophen (APAP)-mediated hepatotoxicity., [Material and Methods]: SIRT1 expression was analyzed in APAP-induced liver failure in humans and mice. Hepatotoxicity was assessed in wild-type and transgenic mice overexpressing SIRT1 (SIRT1 Tg) poisoned with APAP (300 mg/kg). Raw 264.7 and peritoneal macrophages were treated with APAP and conditioned medium (CM) was added to mouse hepatocytes. siRNA was used to reduce inflammatory mediators in hepatocytes., [Results]: SIRT1 protein levels decreased in human and mouse livers following APAP overdose. SIRT1-Tg mice maintained higher levels of SIRT1 upon APAP injection than wild-type mice and were protected against hepatotoxicity by modulation of antioxidant systems and restrained inflammatory responses, with decreased oxidative stress, pro-inflammatory cytokine mRNA levels, nuclear factor kappa B (NFκB) signaling, and cell death. Mouse hepatocytes stimulated with conditioned medium of APAP-treated macrophages (APAP-CM) showed decreased SIRT1 levels; an effect mimicked by interleukin 1β (IL1β), an activator of NFκB. This negative modulation was abolished by neutralizing IL1β in APAP-CM or silencing p65-NFκB in hepatocytes. APAP-CM of macrophages from SIRT1-Tg mice failed to downregulate SIRT1 protein levels in hepatocytes. In vivo administration of the NFκB inhibitor BAY 11-7082 preserved SIRT1 levels and protected from APAP-mediated hepatotoxicity., [Conclusion]: SIRT1 protein levels are downregulated by IL1β/NFκB signaling in APAP hepatotoxicity, resulting in inflammation and oxidative stress. Thus, maintenance of SIRT1 during APAP overdose by inhibiting NFκB might be clinically relevant. Our work evidenced the unique role of SIRT1 in APAP hepatoprotection by targeting oxidative stress and inflammation., This work was funded by SAF2015-65267-R (MINECO/FEDER), CIBERdem (ISCIII, Spain), INFLAMES (ISCIII PIE14/00045, co-funded by ERDF, “Investing in your future”) to A.M.V; IJCI-2014-19381 (MINECO/FEDER) to P.R and A.M.V; SAF2014-52009-R (MINECO/FEDER) to S.A; SAF2015-63904-R (MINECO/FEDER) to M.M.; CP14/00181 (ISCIII/FEDER) to A. G-R; PI13/00021 (ISCIII/FEDER) to J.M. CIBERehd (ISCIII, Spain) to A. G-R and J.M; Grant 37/371 from Al Jouf University (to M.A.M). We also acknowledge H2020 Marie Sklodowska-Curie ITN-TREATMENT (Grant Agreement number 721236) (European Commission).
Docta Complutense
Publicación Artículo científico (JournalArticle)

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

  • González-Rodríguez, Águeda
  • Valdecantos, M. Pilar
  • Rada, Patricia
  • Addante, Annalisa
  • Barahona, Inés
  • Rey, Esther
  • Pardo, Virginia
  • Ruiz, Laura
  • Laiglesia, Laura M.
  • Moreno-Aliaga, María J.
  • García-Monzón, Carmelo
  • Sánchez Muñoz, Aranzazu
  • Martínez Valverde, Ángela María
Objectives: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries. Protein tyrosine phosphatase 1B (PTP1B), a negative modulator of insulin and cytokine signaling, is a therapeutic target for type 2 diabetes and obesity. We investigated the impact of PTP1B deficiency during NAFLD, particularly in non-alcoholic steatohepatitis (NASH). Methods: NASH features were evaluated in livers from wild-type (PTP1BWT) and PTP1B-deficient (PTP1BKO) mice fed methionine/cholinedeficient diet (MCD) for 8 weeks. A recovery model was established by replacing MCD to chow diet (CHD) for 2e7 days. Non-parenchymal liver cells (NPCs) were analyzed by flow cytometry. Oval cells markers were measured in human and mouse livers with NASH, and in oval cells from PTP1BWT and PTP1BKO mice. Results: PTP1BWT mice fed MCD for 8 weeks exhibited NASH, NPCs infiltration, and elevated Fgf21, Il6 and Il1b mRNAs. These parameters decreased after switching to CHD. PTP1B deficiency accelerated MCD-induced NASH. Conversely, after switching to CHD, PTP1BKO mice rapidly reverted NASH compared to PTP1BWT mice in parallel to the normalization of serum triglycerides (TG) levels. Among NPCs, a drop in cytotoxic natural killer T (NKT) subpopulation was detected in PTP1BKO livers during recovery, and in these conditions M2 macrophage markers were upregulated. Oval cells markers (EpCAM and cytokeratin 19) significantly increased during NASH only in PTP1B-deficient livers. HGF-mediated signaling and proliferative capacity were enhanced in PTP1BKO oval cells. In NASH patients, oval cells markers were also elevated. Conclusions: PTP1B elicits a dual role in NASH progression and reversion. Additionally, our results support a new role for PTP1B in oval cell proliferation during NAFLD.